Chicago Partners Investment Group
JBIO icon

Chicago Partners Investment Group’s Jade Biosciences JBIO Stock Holding History

Chicago Partners Investment Group’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-290
Closed -$226K – 591
2022
Q2 		$226K Buy
+290
New +$138K 0.02% 509
2022
Q1 		– Sell
-424
Closed -$140K – 571
2021
Q4 		$140K Sell
424
-35
-8% -$17.7K 0.01% 539
2021
Q3 		$284K Buy
+459
New +$257K 0.02% 453

Other funds holding JBIO

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Chicago Partners Investment Group's JBIO Position: Q3 2022 in Review

Chicago Partners Investment Group sold out of Jade Biosciences (JBIO) in Q3 2022, closing a stake of 290 shares — an estimated $226K sold.

Chicago Partners Investment Group first reported a position in JBIO in Q3 2021 and held it in 3 quarters. The position peaked at $284K in Q3 2021. 55 funds tracked by Wall St. Rank hold JBIO as of Q3 2022.

  • Chicago Partners Investment Group reported no remaining Jade Biosciences position as of Q3 2022 after selling out during the quarter.
  • Chicago Partners Investment Group sold 290 Jade Biosciences shares in Q3 2022, an estimated $226K.
  • Chicago Partners Investment Group first reported a position in Jade Biosciences in Q3 2021 and held it in 3 quarters.
  • Chicago Partners Investment Group's Jade Biosciences position peaked at $284K in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2022.

Based on Chicago Partners Investment Group's 13F filing for Q3 2022, filed 9 Nov 2022.